The effect of dihydroergotoxine-ethanesulphonate (Redergam) on the basal and with 3-(3,4-dihydroxyphenyl)-L-alanine (L-DOPA) stimulated somatotrophic secretion of diabetic patients.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D003920:Diabetes Mellitus / Q000503:physiopathology*; D004088:Dihydroergotoxine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004341:Drug Evaluation; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D010903:Pituitary Gland, Anterior / Q000378:metabolism*; D012636:Secretory Rate / Q000187:drug effects
D004088:Dihydroergotoxine; D007980:Levodopa; D013006:Growth Hormone